Caris Life Sciences, Inc. (CAI) Profit Margins
Over the twelve months to 2026-06-30, Caris Life Sciences, Inc. (CAI) had gross margin 69.7%, operating margin 15.5%, net margin 10.6%, free cash flow margin 12.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | 29.2% | 43.4% | 66.4% | 69.7% | |
| Operating margin | -104.4% | -62.4% | 5.6% | 15.5% | |
| Net margin | -111.5% | -68.4% | -8.4% | 10.6% | |
| FCF margin | -97.5% | -61.5% | 8.2% | 12.5% |
USD billions · SEC XBRL
Caris Life Sciences, Inc. — questions
- What is Caris Life Sciences, Inc.'s gross margin?
- 69.7% over the twelve months to 2026-06-30.
- What is Caris Life Sciences, Inc.'s operating margin?
- 15.5% over the twelve months to 2026-06-30.
- What is Caris Life Sciences, Inc.'s net profit margin?
- 10.6% over the twelve months to 2026-06-30.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.